Medanta Breaks Major Resistance, Eyes New Highs

Global Health, operating under the Medanta brand, continues to strengthen its fundamental profile through strong patient volumes, capacity expansion and improving contribution from newer hospitals. Q1 FY27 consolidated total income rose 26.2% YoY to ₹1,326 crore, while EBITDA increased 23.5% to ₹315 crore. Patient volumes remained robust, with IP volumes growing 28% and OP volumes rising 34% YoY, highlighting healthy demand across the network. The Noida facility is also moving closer to profitability, reducing the drag from newer capacity. Management is simultaneously pursuing a large expansion pipeline, including the revised Guwahati project that will increase planned capacity to 650 beds. Technically, Medanta has delivered a significant breakout from a multi-year descending resistance structure visible on the daily chart. The stock had been consolidating within a broad contracting formation since the 2024 peak, with resistance gradually declining from the ₹1,550–₹1,600 region while the lower boundary established support near ₹950–₹1,000. The recent rally has taken the price through the upper trendline and the previous resistance around ₹1,400, with the stock now trading close to its lifetime-high zone. This breakout is important because it marks a transition from a prolonged consolidation phase into potential price discovery. Sustained trading above ₹1,400–₹1,420 would keep the breakout intact, while a decisive move above the recent high near ₹1,450 can reinforce the bullish structure and open the possibility of fresh all-time highs. On the downside, ₹1,350–₹1,400 becomes the first important support zone, followed by ₹1,250–₹1,300. As long as the breakout zone holds on closing basis, the technical bias remains firmly bullish.